Ethics, Evidence and Economics in the Pursuit of "Personalized Medicine"

被引：11
作者：
Lewis, Jan [1 ]
Lipworth, Wendy [2 ]
Kerridge, Ian [1 ]
机构：
[1] Univ Sydney, Ctr Values Eth & Law Med, Univ Sydney Med Fdn Bldg K25, Sydney, NSW 2006, Australia
[2] Univ New South Wales, Australian Inst Hlth Innovat, Sydney, NSW 2052, Australia
来源：
JOURNAL OF PERSONALIZED MEDICINE | 2014年 / 4卷 / 02期
关键词：
individualized medicine; pharmacology; ethics; economics; medicine; knowledge;
D O I：
10.3390/jpm4020137
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
Despite enthusiastic advocacy for what personalized medicine might be able to deliver and major investments into the development of this, there remain disappointingly few examples of personalized medicine in routine clinical practice today, particularly in high areas of unmet need such as cancer. We believe that this is because personalized medicine challenges the moral, economic and epistemological foundations of medicine. In this article, we briefly describe the scientific premises underpinning personalized medicine, contrast these with traditional paradigms of drug development, and then consider the ethical, economic and epistemological implications of this approach to medicine.
引用
收藏
页码：137 / 146
页数：10
相关论文
共 15 条
  • [1] The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts
    Abboud, Camille
    Berman, Ellin
    Cohen, Adam
    Cortes, Jorge
    DeAngelo, Daniel
    Deininger, Michael
    Devine, Steven
    Druker, Brian
    Fathi, Amir
    Jabbour, Elias
    Jagasia, Madan
    Kantarjian, Hagop
    Khoury, Jean
    Laneuville, Pierre
    Larson, Richard
    Lipton, Jeffrey
    Moore, Joseph O.
    Mughal, Tariq
    O'Brien, Susan
    Pinilla-Ibarz, Javier
    Quintas-Cardama, Alfonso
    Radich, Jerald
    Reddy, Vishnu
    Schiffer, Charles
    Shah, Neil
    Shami, Paul
    Silver, Richard T.
    Snyder, David
    Stone, Richard
    Talpaz, Moshe
    Tefferi, Ayalew
    Van Etten, Richard A.
    Wetzler, Meir
    Abruzzese, Elisabetta
    Apperley, Jane
    Breccia, Massimo
    Byrne, Jenny
    Cervantes, Francisco
    Chelysheva, Ekaterina
    Clark, R. E.
    de Lavallade, Hugues
    Dyagil, Iryna
    Gambacorti-Passerini, Carlo
    Goldman, John
    Haznedaroglu, Ibrahim
    Hjorth-Hansen, Henrik
    Holyoake, Tessa
    Huntly, Brian
    le Coutre, Philipp
    Lomaia, Elza
    [J]. BLOOD, 2013, 121 (22) : 4439 - 4442
  • [2] Report of an international expanded access program of imatinib in adults with Philadelphia chromosome positive leukemias
    Capdeville, R.
    Krahnke, T.
    Hatfield, A.
    Ford, J. M.
    Van Hoomissen, I.
    Gathmann, I.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 (07) : 1320 - 1326
  • [3] Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
    Druker, BJ
    Tamura, S
    Buchdunger, E
    Ohno, S
    Segal, GM
    Fanning, S
    Zimmermann, J
    Lydon, NB
    [J]. NATURE MEDICINE, 1996, 2 (05) : 561 - 566
  • [4] Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
    Druker, Brian J.
    Guilhot, Francois
    O'Brien, Stephen G.
    Gathmann, Insa
    Kantarjian, Hagop
    Gattermann, Norbert
    Deininger, Michael W. N.
    Silver, Richard T.
    Goldman, John M.
    Stone, Richard M.
    Cervantes, Francisco
    Hochhaus, Andreas
    Powell, Bayard L.
    Gabrilove, Janice L.
    Rousselot, Philippe
    Reiffers, Josy
    Cornelissen, Jan J.
    Hughes, Timothy
    Agis, Hermine
    Fischer, Thomas
    Verhoef, Gregor
    Shepherd, John
    Saglio, Giuseppe
    Gratwohl, Alois
    Nielsen, Johan L.
    Radich, Jerald P.
    Simonsson, Bengt
    Taylor, Kerry
    Baccarani, Michele
    So, Charlene
    Letvak, Laurie
    Larson, Richard A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (23) : 2408 - 2417
  • [5] The ethics of attaching research conditions to access to new health technologies
    Holland, Stephen
    Hope, Tony
    [J]. JOURNAL OF MEDICAL ETHICS, 2012, 38 (06) : 366 - 371
  • [6] Knaul FM., 2011, CLOSING CANC DIVIDE
  • [7] Personalized medicine: transforming drug development and healthcare
    Lee, Vincent H. L.
    [J]. THERAPEUTIC DELIVERY, 2010, 1 (05) : 615 - 619
  • [8] The economic evaluation of personalised oncology medicines: ethical challenges
    Lewis, Jan R. R.
    Lipworth, Wendy L.
    Kerridge, Ian H.
    Day, Richard O.
    [J]. MEDICAL JOURNAL OF AUSTRALIA, 2013, 199 (07) : 471 - 473
  • [9] Media influence on Herceptin subsidization in Australia: application of the rule of rescue?
    MacKenzie, Ross
    Chapman, Simon
    Salkeld, Glenn
    Holding, Simon
    [J]. JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 2008, 101 (06) : 305 - 312
  • [10] McClellan M. B., 2008, EVIDENCE BASED MED C
12